Mallinckrodt ARD LLC clinical trials
Acquired by Keenova Therapeutics plc, Aug 14, 2014 · source ↗
The registry lists 3 studies whose lead sponsor is Mallinckrodt ARD LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 4, 2021.
Before and after it joined Keenova Therapeutics plc
- First submitted before Mallinckrodt ARD LLC became part of Keenova Therapeutics plc
- 0
- First submitted after Mallinckrodt ARD LLC became part of Keenova Therapeutics plc
- 3
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Mallinckrodt ARD LLC3 studies
Something wrong with this grouping? Tell us on the Keenova Therapeutics plc page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Keenova Therapeutics plc studies →
- Acthar for Treatment-Resistant or Treatment-Intolerant ProteinuriaCompletedNCT02633046Phase 4
Sponsor listed in the registry: Mallinckrodt ARD LLC · First submitted after Mallinckrodt ARD LLC became part of Keenova Therapeutics plc
- Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)TerminatedNCT03126760Phase 4
Sponsor listed in the registry: Mallinckrodt ARD LLC · First submitted after Mallinckrodt ARD LLC became part of Keenova Therapeutics plc
- A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular DystrophyTerminatedNCT03400852Phase 2
Sponsor listed in the registry: Mallinckrodt ARD LLC · First submitted after Mallinckrodt ARD LLC became part of Keenova Therapeutics plc